Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rheumatoid arthritis patients fulfilling Korean National Health Insurance reimbursement guidelines for anti-tumor necrosis factor-α treatment and comparison to other guidelines.
Hur JW, Choe JY, Kim DW, Kim HA, Kim SH, Kim WU, Kim YS, Lee HS, Lee SH, Park SH, Park W, Park YB, Suh CH, Shim SC, Song YW, Yoon BY, Yu DY, Yoo DH. Hur JW, et al. Rheumatol Int. 2015 Nov;35(11):1817-23. doi: 10.1007/s00296-015-3353-7. Epub 2015 Sep 5. Rheumatol Int. 2015. PMID: 26342296
Simplified disease activity changes in real-world practice: a nationwide observational study of seropositive rheumatoid arthritis patients with moderate-to-high disease activity.
Shin K, Kim SS, Lee SH, Hong SJ, Choi SJ, Choe JY, Lee SG, Cha HS, Lee EY, Park SH, Hur JW, Na SS, Suh CH, So MW, Choi SW, Sheen DH, Park W, Lee SS, Ryu WH, Kim JS, Song JS, Lee HS, Kim SH, Yoo DH. Shin K, et al. Among authors: hur jw. Korean J Intern Med. 2020 Jan;35(1):231-239. doi: 10.3904/kjim.2018.137. Epub 2019 Jan 28. Korean J Intern Med. 2020. PMID: 30685961 Free PMC article.
Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study.
Park MC, Matsuno H, Kim J, Park SH, Lee SH, Park YB, Lee YJ, Lee SI, Park W, Sheen DH, Choe JY, Choi CB, Hong SJ, Suh CH, Lee SS, Cha HS, Yoo B, Hur JW, Kim GT, Yoo WH, Baek HJ, Shin K, Shim SC, Yang HI, Kim HA, Park KS, Choi IA, Lee J, Tomomitsu M, Shin S, Lee J, Song YW. Park MC, et al. Among authors: hur jw. Arthritis Res Ther. 2019 May 21;21(1):122. doi: 10.1186/s13075-019-1910-2. Arthritis Res Ther. 2019. PMID: 31113455 Free PMC article. Clinical Trial.
Comparison of the efficacy and safety of CELBESTA® versus CELEBREX® in patients with rheumatoid arthritis: a 6-week, multicenter, double-blind, double-dummy, active-controlled, randomized, parallel-group, non-inferiority phase 4 clinical trial.
Kim HS, Choi WH, Kim BY, Kim SS, Lee SI, Kim SH, Choi SJ, Kim GT, Hur JW, Lee MS, Kim YS, Hong SJ. Kim HS, et al. Among authors: hur jw. J Int Med Res. 2020 Jun;48(6):300060520931323. doi: 10.1177/0300060520931323. J Int Med Res. 2020. PMID: 32589073 Free PMC article. Clinical Trial.
Real-world effectiveness of a single conventional disease-modifying anti-rheumatic drug (cDMARD) plus an anti-TNF agent versus multiple cDMARDs in rheumatoid arthritis: a prospective observational study.
So MW, Kim SH, Kim DW, Sung YK, Choe JY, Lee SI, Hur JW, Lee HS, Lee SH, Kim JR, PharmD. So MW, et al. Among authors: hur jw. J Rheum Dis. 2024 Apr 1;31(2):86-96. doi: 10.4078/jrd.2023.0045. Epub 2024 Jan 29. J Rheum Dis. 2024. PMID: 38559796 Free PMC article.
165 results